Stoke Therapeutics (STOK) Competitors $12.07 -0.04 (-0.33%) (As of 12/2/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends STOK vs. WVE, CGON, IDYA, LBPH, KROS, CNTA, AKRO, MIRM, AMPH, and JANXShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Wave Life Sciences (WVE), CG Oncology (CGON), IDEAYA Biosciences (IDYA), Longboard Pharmaceuticals (LBPH), Keros Therapeutics (KROS), Centessa Pharmaceuticals (CNTA), Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), Amphastar Pharmaceuticals (AMPH), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Wave Life Sciences CG Oncology IDEAYA Biosciences Longboard Pharmaceuticals Keros Therapeutics Centessa Pharmaceuticals Akero Therapeutics Mirum Pharmaceuticals Amphastar Pharmaceuticals Janux Therapeutics Stoke Therapeutics (NASDAQ:STOK) and Wave Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership. Is STOK or WVE more profitable? Wave Life Sciences has a net margin of -66.50% compared to Stoke Therapeutics' net margin of -629.90%. Stoke Therapeutics' return on equity of -54.45% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics-629.90% -54.45% -40.77% Wave Life Sciences -66.50%-280.57%-52.90% Which has more volatility and risk, STOK or WVE? Stoke Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.21, indicating that its stock price is 221% less volatile than the S&P 500. Does the media favor STOK or WVE? In the previous week, Wave Life Sciences had 5 more articles in the media than Stoke Therapeutics. MarketBeat recorded 6 mentions for Wave Life Sciences and 1 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.87 beat Wave Life Sciences' score of 0.87 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Stoke Therapeutics Very Positive Wave Life Sciences Positive Which has better valuation & earnings, STOK or WVE? Wave Life Sciences has higher revenue and earnings than Stoke Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$8.78M72.82-$104.70M-$2.10-5.75Wave Life Sciences$113.31M20.55-$57.51M-$1.11-13.76 Does the MarketBeat Community prefer STOK or WVE? Wave Life Sciences received 255 more outperform votes than Stoke Therapeutics when rated by MarketBeat users. However, 74.48% of users gave Stoke Therapeutics an outperform vote while only 67.85% of users gave Wave Life Sciences an outperform vote. CompanyUnderperformOutperformStoke TherapeuticsOutperform Votes10874.48% Underperform Votes3725.52% Wave Life SciencesOutperform Votes36367.85% Underperform Votes17232.15% Do institutionals and insiders believe in STOK or WVE? 89.7% of Wave Life Sciences shares are owned by institutional investors. 11.3% of Stoke Therapeutics shares are owned by insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend STOK or WVE? Stoke Therapeutics presently has a consensus price target of $20.83, indicating a potential upside of 72.60%. Wave Life Sciences has a consensus price target of $22.22, indicating a potential upside of 45.53%. Given Stoke Therapeutics' higher probable upside, equities research analysts clearly believe Stoke Therapeutics is more favorable than Wave Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryWave Life Sciences beats Stoke Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$639.35M$6.73B$5.20B$8.97BDividend YieldN/A7.94%5.23%4.04%P/E Ratio-5.754.7285.7113.39Price / Sales72.82352.931,469.4286.49Price / CashN/A22.8835.2935.09Price / Book3.385.604.914.96Net Income-$104.70M$151.32M$117.36M$224.10M7 Day Performance2.55%3.14%2.75%2.01%1 Month Performance-6.14%-1.67%1.71%9.79%1 Year Performance205.57%31.88%36.01%29.97% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics3.9905 of 5 stars$12.07-0.3%$20.83+72.6%+205.6%$639.35M$8.78M-5.75100Positive NewsWVEWave Life Sciences4.9831 of 5 stars$15.93+5.5%$22.22+39.5%+177.1%$2.43B$113.31M0.00240Gap UpCGONCG Oncology2.0611 of 5 stars$35.29+1.6%$63.88+81.0%N/A$2.39B$684,000.000.0061Positive NewsIDYAIDEAYA Biosciences4.1793 of 5 stars$27.52+0.6%$53.67+95.0%-13.2%$2.38B$23.39M-11.7480Short Interest ↑LBPHLongboard Pharmaceuticals1.1097 of 5 stars$59.98+0.0%$59.56-0.7%+1,399.5%$2.34BN/A-26.9020KROSKeros Therapeutics3.9554 of 5 stars$56.34-2.4%$88.89+57.8%+85.2%$2.28B$651,000.00-11.08100Short Interest ↓News CoveragePositive NewsCNTACentessa Pharmaceuticals4.0815 of 5 stars$17.26-3.6%$25.83+49.7%+153.0%$2.28B$6.85M-11.5272Short Interest ↑News CoverageAKROAkero Therapeutics4.1709 of 5 stars$32.10flat$46.83+45.9%+81.3%$2.24BN/A-8.5630Positive NewsMIRMMirum Pharmaceuticals3.909 of 5 stars$45.56-1.4%$57.73+26.7%+44.4%$2.19B$307.03M-22.88140Positive NewsAMPHAmphastar Pharmaceuticals4.9158 of 5 stars$45.11-0.2%$60.33+33.7%-20.8%$2.17B$644.40M15.061,761Positive NewsJANXJanux Therapeutics3.9792 of 5 stars$41.03-9.2%$67.70+65.0%+344.5%$2.15B$13.05M-35.2630Analyst ForecastGap Up Related Companies and Tools Related Companies WVE Alternatives CGON Alternatives IDYA Alternatives LBPH Alternatives KROS Alternatives CNTA Alternatives AKRO Alternatives MIRM Alternatives AMPH Alternatives JANX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STOK) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts